A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Skyline Therapeutics
83 participants
Apr 2, 2024
OBSERVATIONAL
Conditions
Summary
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Eligibility
Inclusion Criteria3
- Subjects who only meet all of the following criteria are eligible for this study:
- nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
- Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study
Exclusion Criteria1
- Subjects who are judged by the investigator unsuitable for this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06346600